---
title: "Novo Nordisk makes a comeback, stating that the cardiovascular benefits of the weight-loss version of semaglutide are superior to those of tirzepatide"
description: "Novo Nordisk AS announced the latest data from the STEER study at the 2025 European Society of Cardiology Congress, showing that the weight-loss version of semaglutide is more effective than tirzepati"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255409513.md"
published_at: "2025-09-01T06:33:51.000Z"
---

# Novo Nordisk makes a comeback, stating that the cardiovascular benefits of the weight-loss version of semaglutide are superior to those of tirzepatide

> Novo Nordisk AS announced the latest data from the STEER study at the 2025 European Society of Cardiology Congress, showing that the weight-loss version of semaglutide is more effective than tirzepatide in preventing major adverse cardiovascular events in patients with cardiovascular disease. The study indicates that patients using the weight-loss version of semaglutide have a 57% reduced risk of heart attack, stroke, and cardiovascular-related death

In the competition of GLP-1 weight loss drugs, Novo Nordisk's semaglutide has finally turned the tide with its cardiovascular benefits. On September 1st, reporters learned from Novo Nordisk China that the company announced the latest data from the STEER real-world study at the 2025 European Society of Cardiology Congress held in Madrid, Spain. The STEER study is a retrospective, observational real-world study that evaluated the effectiveness of Wegovy compared to tirzepatide in preventing major adverse cardiovascular events in overweight or obese patients with diagnosed cardiovascular disease but without diabetes. The results showed that, under the condition that the medication interruption during treatment did not exceed 30 days, the weight loss version of semaglutide reduced the risk of heart attack, stroke, and cardiovascular-related death or all-cause mortality by 57% compared to tirzepatide in overweight or obese patients with cardiovascular disease. In the trial, the semaglutide group recorded 15 cardiovascular events, while the tirzepatide group recorded 39 events

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/en/news/275719942.md) |
| Novo Nordisk CFO Karsten Munk Knudsen Sells Shares Worth Over DKK 8.3 Million | Novo Nordisk A/S announced that CFO Karsten Munk Knudsen sold 26,246 shares for DKK 8.3 million at DKK 315.60 each and 3 | [Link](https://longbridge.com/en/news/275652909.md) |
| Novo Nordisk to Manufacture Wegovy in Ireland Facility | Novo Nordisk to Manufacture Wegovy in Ireland Facility | [Link](https://longbridge.com/en/news/275789396.md) |
| Savvy Advisors Inc. Purchases 22,138 Shares of Novo Nordisk A/S $NVO | Savvy Advisors Inc. increased its stake in Novo Nordisk A/S by 83.0% in Q3, acquiring 22,138 shares, bringing its total  | [Link](https://longbridge.com/en/news/275761183.md) |
| Biocon aims for revenue surge with rollout of generic weight-loss drugs | Biocon aims for high double-digit revenue growth with the global launch of generic weight-loss drugs, including versions | [Link](https://longbridge.com/en/news/275900960.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.